Enrollment in a standardized secondary lipid clinic following acute STEMI enabled 60% of patients to achieve their target LDL-C levels within 6 weeks.
Observational (n=50)
No
Does a standardized secondary lipid clinic improve LDL-C target achievement and compliance in patients following acute STEMI?
Implementation of a standardized secondary lipid clinic post-STEMI effectively achieves target LDL-C levels in the majority of patients and facilitates the diagnosis of familial hypercholesterolemia.
Abstract Background The emerging role of secondary lipid clinic following acute myocardial infarction has been well-recognised recent years and this clearly bridges the gap between individualised lipid lowering therapy and long-term therapeutic response , in addition to specialist referral to familial hypercholesterolaemia (FH) screening in a selected population. Aim Our primary objective was to standardise secondary lipid clinic pathway as a complimentary tool for patients presented with acute ST-segment myocardial infarction (STEMI) to ensure optimal lipid control and individualised therapeutic strategies in long term. Method A total of 50 patients (our study population)presented to our tertiary centre with acute ST-segment elevated myocardial infarction (STEMI) and successfully revascularized from 1st August 2024 to 1st July 2025. All of them were enrolled into our secondary lipid clinic with lipid screening with subsequent secondary lipid lowering agent was initiated in all patients as per NICE guideline. A standardised survey was created upon three domains, LDL-C level post-MI periods, self-reported patient compliance and individualised lipid lowering agent during post-infarction period within 6 weeks review time. Result All patients identified (n=50) had reported positive satisfaction with quality of input of secondary lipid clinic following post-infarction periods. Mean age was 77.2 years (range 46-102). Notably, 30 out of 50 patients (60%) had managed to achieve their target LDL-C levels within 6 weeks’ time, with no reported cardiovascular adverse outcomes. Interestingly, 20 remaining patients reported to have upgraded individualised additional second lipid lowering agents for robust control of their LDL-C levels following intense secondary lipid clinic input and among those, 10 out of 20 remaining patients (50%)have been diagnosed as familial hypercholesterolaemia (FH) , with further provision of individualised genetic screening and specific lipoprotein testing within short pace of time following post-infarction periods. Conclusion The implementation of standardised secondary lipid clinic during post-infarction periods has led to significant improvement in patient quality of care and potential reduction in risk of future secondary cardiovascular outcomes due to poor compliance in target LDL-C levels in long term.
K K K Kyaw (Mon,) conducted a observational in Acute ST-segment elevated myocardial infarction (STEMI) (n=50). Standardized secondary lipid clinic was evaluated on Achievement of target LDL-C levels within 6 weeks. Enrollment in a standardized secondary lipid clinic following acute STEMI enabled 60% of patients to achieve their target LDL-C levels within 6 weeks.